Wolf AB - Search Results

1

Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.

Quinn CM, Rajarajan P, Gill AJ, Kopinsky H, Wolf AB, de Camargo CS, Lamb J, Bacon TE, Murray JC, Probasco JC, Galetta KM, Kantor D, Coyle P, Bhise V, Alvarez E, Conway SE, Bhattacharyya S, Kister I. Quinn CM, et al. Among authors: wolf ab. Neurology. 2024 Dec 10;103(11):e210003. doi: 10.1212/WNL.0000000000210003. Epub 2024 Nov 14. Neurology. 2024. PMID: 39541548

2

Rituximab-induced serum sickness in multiple sclerosis patients.

Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Wolf AB, et al. Mult Scler Relat Disord. 2019 Nov;36:101402. doi: 10.1016/j.msard.2019.101402. Epub 2019 Sep 17. Mult Scler Relat Disord. 2019. PMID: 31542710

3

COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy.

Wolf A, Alvarez E. Wolf A, et al. Neurol Clin Pract. 2021 Aug;11(4):358-361. doi: 10.1212/CPJ.0000000000001088. Neurol Clin Pract. 2021. PMID: 34484934 Free PMC article.

4

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.

Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Vollmer BL, et al. Among authors: wolf ab. Front Neurol. 2022 Jan 25;12:799138. doi: 10.3389/fneur.2021.799138. eCollection 2021. Front Neurol. 2022. PMID: 35145470 Free PMC article.

5

Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience.

Wolf AB, Alvarez E, Corboy JR. Wolf AB, et al. JAMA Neurol. 2024 Jan 1;81(1):87. doi: 10.1001/jamaneurol.2023.4395. JAMA Neurol. 2024. PMID: 37983039 No abstract available.

6

Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Wolf AB, Corboy JR. Wolf AB, et al. Neurol Clin Pract. 2024 Oct;14(5):e200330. doi: 10.1212/CPJ.0000000000200330. Epub 2024 Jun 10. Neurol Clin Pract. 2024. PMID: 38919933

7

Challenging Cases in Neuroimmunology.

Shah AA, Wolf AB, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR. Shah AA, et al. Among authors: wolf ab. Semin Neurol. 2022 Dec;42(6):695-707. doi: 10.1055/s-0042-1760100. Epub 2023 Jan 23. Semin Neurol. 2022. PMID: 36690027

8

Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability.

Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Flachenecker P, et al. Mult Scler. 2001 Oct;7(5):327-34. doi: 10.1177/135245850100700509. Mult Scler. 2001. PMID: 11724449 Clinical Trial.

9

The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population.

Carlson AM, Sollero CEV, Wolf AB, Sillau S, Schmitt BL, Money KM, Nair KV, Piquet AL, Bennett JL. Carlson AM, et al. Among authors: wolf ab. Ann Clin Transl Neurol. 2024 Dec 21. doi: 10.1002/acn3.52268. Online ahead of print. Ann Clin Transl Neurol. 2024. PMID: 39708292 Free article.

10

Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance.

Flachenecker P, Wolf A, Krauser M, Hartung HP, Reiners K. Flachenecker P, et al. J Neurol. 1999 Jul;246(7):578-86. doi: 10.1007/s004150050407. J Neurol. 1999. PMID: 10463360

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters